Axon / Taser Favorability Statistics 2023

By Ethan Ace, Published Jan 20, 2023, 08:39am EST (Info+)

Axon and Taser are best known for body-worn cameras and less-lethal weapons, but what do integrators think of them?

IPVM Image

In this report, IPVM examines statistics and commentary from 185 security integrators on Axon's positioning, pros, and cons.

Favorability *******

**** **** ***-****** ** *********** ******** Do *** ****, **** ** ********** 15% ****** * ******* ******* (**% total). ***** ***** **** ********/******** ********, their *** ************ ** * **** positive, +*%.

IPVM Image

Weaker ******* **

******* *** **, ****'* *** *****'* net ************ ***** ** -*% ****** +9% ******, **** **** ****** ******* opinion, ** ****.

IPVM Image

Most ***********: Don't ****

**** *********** *** *** **** *** Axon/Taser **** ** *** * ******* opinion, **** **** * ******* ** positive *** ******** *****.

  • "***** ***** ** ****. *****’* **** or ********** **** **** ******* ** all."
  • "* **** ***** *** *** *********** with ****/*****. *'** **** **** ******* via *** **** *******."
  • "* **** ** ********** ***** ****. However * *** ***** **** ** a *** ** **** *** ******* that **** ********.... **** **** ** doing ********* *****."
  • "***'* *** **** ** *** ***** Axon/Taser. * **** *** *** ***** videos ** *** **** *** *** time *** ****** ** ** * decent ******* ******."
  • "* ******* **** *** *** **** of *** ********* ****** *** ********. we **** *** *** * **** to ****** *** ** ***** ** our ******** ****."
  • "** **** *** ** ******** **** Axon. ** ******* *** ** **** once ***** **** ******** ******** *** never ***** ****."
  • "*'** **** ****, **** **** *******, but **** ** ******** **********"
  • "************* * ** *** **** ******** about **** ******* ******."
  • "**** **** ** ****. *****'* **** or ********** ***** *********."
  • "***** **** **** ** *** **** up ** ** ******."
  • "***** **** ** *** *** ********** with ****."
  • "** ***'* **** ********** **** ****/*****."
  • "* ** *** ******** **** **** company."
  • "** **** *** **** **** /*****."
  • "**** ***** **** ***** *******."
  • "** ********** **** *******."
  • "**** *** *********** ****."
  • "***** **** ***** ** ****."
  • "* **** *** ***** ** ****."
  • "** ********** **** ****."
  • "* ** *** *** **** *******."
  • "**** ***** **** ****."
  • "***** ***** ** ****."
  • "*****'* **** ****."
  • "***** ****, *****."
  • "*** ******** ****."
  • "*****’* ****."
  • "***** ****."
  • "*/*" [**].

******* *********** **** **** ****/***** **** not ********* ** ***** *******/******:

  • "***** *** *********** ** ** *******, Not ******** **** **** - *** seen ** **** ** *** ***********." (Norway)
  • "**** ***’* ****** ******** ** *** market. ***** ********** ** *********, *** we **** ** ****** ********** ******* with ****." (**)
  • "******** ******* ****/***** ** *** *** well ***** ** *****, ** ** not **** **** ***** ****."
  • "** * ** ***** ** *** UK * ** *** ******** **** this *******."
  • "**** ** *** ********* ** **** region." (******** & ******)
  • "*** **** ** **é***, ******."
  • "*** *** *********."

*******, ****** ******** **** **** **** who ****/***** ****, *** ****** **** not ** *** *** *********** ********:

  • "* **** ******* ** *** ***** Axon ** *'* *** ** **** market."
  • "** ********** **** ****. * ******* Axon ** *** ** *** ******* business. ** ***'* *** **** *** do ** **** *** *********** ** use ****."
  • "* **** ** ***** **** **** part ** *** ********."
  • "*** ** **** ******, *** ******** with ****."
  • "******** *** ** *****."

Positive: ****** ******** ** ***** ********

***** ********** ********** ******* ****/***** ********, especially ****-**** ******* *** ******** **********.

  • "**** **** **** ********. ** ***'* use/sell ****, *** ** ** * lot ** **** **** *** *********** and **** *** *** **** *********** of **** ********. ** **** ** deal **** ********.*** ************ **** ****'* use ** ** ***** ******** **** our *** *******. ***** ******* ** always ****** *******, **** ****** ** are *** * ******** ** ****** for ****."
  • "* ***** **** **** **** ****** qualities ** *** ********** *** ******* of ****/*******. ** ** ******** ** control ******** ********* *** **** **** to **** **** **** ***** ** collating **. * **** ***** ***** body **** ******** **** ****** **** good *** ****** ***********."
  • "**** ** ****. ** *** **** interview **** ***** *** ****'* **** to ** **** ***** **** *******. They ***'* ****** ****** ************* *** rather **** *** ** *********. **** also *** * ****** ******* *** takes **** ***** *** ****** ** happen ** ******."
  • "**** ****** ********* ** ******** **** complement **** *****, **** ******* ***** and * **** *** **** ***** software *****."
  • "**** ***** ** ****** *****. ****** also **** ***** (******* ** ******** to ****). * ***'* **** ****** of ***** ******** ** * ***'* do *** *********** ********."
  • "** ******* **** *** **** ****, so **** *** ****** *********** *** if *** ** **** **** * don't ***** ***. **** *******, **** support, **** *** ***** *** ******** it."
  • "* *****'* **** ***** ******** **********, but *'** **** **** ******** *** I've ******* *** *** ******** **** they **** ****** ** *** *********. They **** ****-*****."
  • "*** ******* **** ** ****** *** availability ** ******** ** ****** **** others."
  • "**** ***** ** ** *** ******** standard. **** **** ******* ********."

Negative: ******** *********, *** ********

***** ********** ********** **** ***** ***** Axon's ******** *********, *** *** ******* of ********.

  • "* **** ****** **** **** ** Agencies **** *** **** ******* ** their ********* *** ********* ** *** footage. * ******* ** ** ******* and ********* ***** *** *** **** go ** ****** *** * ****** support **."
  • "* ****** ******* ******* ** ********** to ***** ********* ****** ******* ** non-lethal, *** **** ***** ****** **** their ******* ******** **** *** *** any ****** ** **** *** **** Axon."
  • "** *** ****** ********** ** **** of ***** **** ************ ********* *** unfortunately **** *** ******** ******* **** it ***** **** ** *** **** field **** ***** *********** **** *** solution."
  • "*** ***** *********** *** *** ****** to *** ******* ** *****. **** have *** *** *********** ****** ****** down. *** ************ ******** *** ***** integrate **** *** **** ***, *** thus * ***** *** **** ***-**** body ****."
  • "** **** **** *** *** ***** competing ********. *** **** ** **** used **** *** **** ******** *** not ***** **** ****."
  • "********* ******* *** ******** ************ ***** out *** ******** **** ****** *******."
  • "**** **** ******. **, ******* ***'* have **** **** ********."
  • "*** *** *** ***** *****."

*******

****'* **** ** *********** ***** *********** is *** ********, ***** ***** ****** sales ********, ****** ** *** ***********, with ** ********** *******. *******, ** expect ***** ********* ** *** *********** to ********, ** **** ******** **** standardized ** ****/***** *** ***** ** the ******** *** ***** ****** ** word-of-mouth **************.

Comments (2)

* ***'* *** **** ******* *** packed **** ***********. *'* *** **** sure *** ***'* **** *********** ** a ******* **** **** ***** ******. I ** ********** **** *** ******.

IPVM Image

Agree
Disagree
Informative
Unhelpful
Funny

******* (*) **** ** *** * fairly **** ******* ***** **** $* billion ** ******* *** (*) ** do *** **** ** ******* *** answers ***** **. ** ***** **** been **** ******** *********** **** ******, think **** *** **** *** *** and ******* **** **********, ***.

**** ** **** ********* **** ******* into ********, *.*.***** ****** $** ******* **** ************** ****** $**+ ******* *** ** Axon. ** ****, **** *** ****** to ****** **** **** ******** ** security *************, ** **** ***** ** a ******** ** ******** **** ***** forward ** ****.

Agree
Disagree
Informative
Unhelpful
Funny
Login to read this IPVM report.
Why do I need to log in?
IPVM conducts reporting, tutorials and software funded by subscriber's payments enabling us to offer the most independent, accurate and in-depth information.
Loading Related Reports